Allopurinol is widely used for hyperuricemia-related diseases such as gout, Lesch-Nyhan syndrome, and recurrent urate kidney stones.
There is a reported mortality rate of 20% to 25% for allopurinol hypersensitivity syndrome (AHS).
Guidelines have been developed by the Clinical Pharmacogenomics Implementation Consortium that reviewed the literature that supports HLA-B*5801 genotyping prior to use of allopurinol. The consortium recommend that allopurinol should not be prescribed to patients who test positive for the allele.
Guidelines developed by the 2012 American College of Rheumatology for Management of Gout recommend that HLA-B*5801 testing should be considered in select patient subpopulations at an elevated risk for AHS.
Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Day(s) and Time(s) Test Performed: Monday and Thursday
Mayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. This site provides the latest medical, operational and educational news from Mayo Medical Laboratories.